Company Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 30, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Gerald Quirk |
Contact Details
Address: 35 CambridgePark Drive, 4th Floor Cambridge, Massachusetts 02140 United States | |
| Phone | 617 744 1340 |
| Website | syros.com |
Stock Details
| Ticker Symbol | SYRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001556263 |
| CUSIP Number | 87184Q107 |
| ISIN Number | US87184Q2066 |
| Employer ID | 45-3772460 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald E. Quirk Esq., J.D. | President and Chief Executive Officer |
| Dr. James E. Bradner M.D. | Founder |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 144 | Filing |
| Dec 13, 2024 | 144 | Filing |
| Dec 13, 2024 | 144 | Filing |
| Dec 13, 2024 | 144 | Filing |
| Dec 10, 2024 | 144 | Filing |
| Dec 6, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |
| Nov 19, 2024 | 144 | Filing |
| Nov 18, 2024 | 144 | Filing |